دورية أكاديمية
أعرض في EDS

Quality of life in allergic rhinitis patients treated with intralymphatic immunotherapy (ILIT): A 19-year follow-up.

التفاصيل البيبلوغرافية
العنوان: Quality of life in allergic rhinitis patients treated with intralymphatic immunotherapy (ILIT): A 19-year follow-up.
المؤلفون: Adlany YK; Department of Dermatology, University of Zurich, Raemistrasse 100, Zurich, Switzerland., Šošić L; Department of Dermatology, University of Zurich, Raemistrasse 100, Zurich, Switzerland., Senti G; University Hospital Zurich, Raemistrasse 100, Zurich, Switzerland., Lang CCV; Department of Dermatology, University Hospital Zurich, Raemistrasse 100, Zurich, Switzerland., Wüthrich B; Department of Dermatology, University of Zurich, Raemistrasse 100, Zurich, Switzerland., Kündig TM; Department of Dermatology, University of Zurich, Raemistrasse 100, Zurich, Switzerland.; Department of Dermatology, University Hospital Zurich, Raemistrasse 100, Zurich, Switzerland., Johansen P; Department of Dermatology, University of Zurich, Raemistrasse 100, Zurich, Switzerland.; Department of Dermatology, University Hospital Zurich, Raemistrasse 100, Zurich, Switzerland.
المصدر: The journal of allergy and clinical immunology. Global [J Allergy Clin Immunol Glob] 2022 Oct 27; Vol. 2 (1), pp. 43-50. Date of Electronic Publication: 2022 Oct 27 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 9918453488706676 Publication Model: eCollection Cited Medium: Internet ISSN: 2772-8293 (Electronic) Linking ISSN: 27728293 NLM ISO Abbreviation: J Allergy Clin Immunol Glob Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [New York] : Elsevier Inc., [2022]-
مستخلص: Background: In 2002-2005, we conducted a phase I/II clinical trial where a new allergy immunotherapy (AIT) route was introduced: intralymphatic immunotherapy (ILIT). Ultrasound guidance allowed injection of allergen directly into inguinal lymph nodes. Grass pollen-allergic patients received 3 injections with 1-month intervals. The short ILIT was more patient-friendly, required lower dosing, and was comparable with SCIT regarding short-term efficacy, which was used as a reference.
Objective: Nineteen years after ILIT, the same patients were followed up to assess the long-term effect on quality of life and efficacy of the treatment.
Methods: Patients who received ILIT and SCIT in 2002-2005 and an additional group of patients, who completed SCIT in 2015-2018, were recruited. All participants received a trial-specific in-house questionnaire and a standardized Rhinoconjunctivitis Quality of Life Questionnaire. Data were recorded off- (February 2021) and on- (May-June 2021) season. Descriptive statistics were applied.
Results: Of 58 and 54 patients who originally received ILIT or SCIT, 25 (43%) and 29 (54%) patients, respectively, returned the questionnaires for analysis. Four (16%) and 3 (11%) of the ILIT and SCIT patients, respectively, developed complete protection against grass pollen-mediated rhinitis, whereas another 15 (60%) and 20 (69%) expressed satisfaction with the received AIT. In both groups, any persistent symptoms were reported as mild. Medication usage in the ILIT and SCIT groups was comparable. Nineteen (76%) and 23 (79%) patients, respectively, expressed satisfaction with their AIT.
Conclusions: Grass pollen ILIT leads to long-term significant improvement in rhinitis-associated quality of life 19 years after treatment, and the ILIT quality-of-life effect was not inferior to that of SCIT.
(© 2022 The Author(s).)
References: Allergy Asthma Immunol Res. 2017 May;9(3):272-277. (PMID: 28293934)
J Allergy Clin Immunol. 1999 Aug;104(2 Pt 1):364-9. (PMID: 10452758)
Allergy Asthma Clin Immunol. 2006 Sep 15;2(3):117-23. (PMID: 20525156)
Allergy. 1997 Mar;52(3):331-4. (PMID: 9140525)
J Allergy Clin Immunol. 2021 Mar;147(3):1011-1019. (PMID: 32679209)
Curr Opin Allergy Clin Immunol. 2017 Feb;17(1):55-59. (PMID: 27906697)
Clin Exp Allergy. 1991 Jan;21(1):77-83. (PMID: 2021881)
Allergy. 2021 Jun;76(6):1859-1861. (PMID: 33099797)
Eur J Immunol. 2005 Dec;35(12):3591-8. (PMID: 16285011)
Allergy Asthma Proc. 2021 Jul 1;42(4):283-292. (PMID: 34187620)
Allergy. 2017 Jan;72(1):13-23. (PMID: 27558586)
Clin Exp Med. 2013 Feb;13(1):67-73. (PMID: 22307736)
Allergy. 2011 Oct;66(10):1345-59. (PMID: 21707645)
World Allergy Organ J. 2022 Jan 27;15(1):100625. (PMID: 35145605)
J Allergy Clin Immunol. 2013 Feb;131(2):412-20. (PMID: 23374268)
Front Allergy. 2022 Mar 16;3:832010. (PMID: 35386649)
J Allergy Clin Immunol. 2020 Mar;145(3):1005-1007.e7. (PMID: 31775016)
N Engl J Med. 1999 Aug 12;341(7):468-75. (PMID: 10441602)
Lancet Reg Health Eur. 2021 Nov 30;13:100275. (PMID: 34901915)
Rhinology. 2021 Jun 1;59(3):236-244. (PMID: 33647073)
Vaccine. 2006 Feb 27;24(9):1389-94. (PMID: 16225968)
Allergy Asthma Immunol Res. 2018 Mar;10(2):180-181. (PMID: 29411559)
Eur J Immunol. 2005 Feb;35(2):568-74. (PMID: 15682446)
Int J Surg. 2012;10(1):28-55. (PMID: 22036893)
J Allergy Clin Immunol. 2018 Oct;142(4):1338-1341.e9. (PMID: 29908212)
Int Arch Allergy Immunol. 1995 Feb;106(2):149-56. (PMID: 7819743)
Pediatr Allergy Immunol. 2021 Jan;32(1):86-91. (PMID: 32810884)
Allergy. 2022 Mar;77(3):883-896. (PMID: 34379802)
Clin Exp Allergy. 2005 Dec;35(12):1591-8. (PMID: 16393325)
Allergy. 2016 Sep;71(9):1366-70. (PMID: 27253988)
Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17908-12. (PMID: 19001265)
Clin Exp Allergy. 2008 Mar;38(3):512-9. (PMID: 18081882)
Allergo J Int. 2014;23(8):282-319. (PMID: 26120539)
Clin Transl Allergy. 2021 Aug 17;11(6):e12055. (PMID: 34429875)
Immunol Allergy Clin North Am. 2016 Feb;36(1):205-13. (PMID: 26617236)
Respir Res. 2016 Jan 27;17:10. (PMID: 26817454)
Respir Res. 2021 Jun 4;22(1):170. (PMID: 34088322)
Ann Allergy Asthma Immunol. 2016 Feb;116(2):168-70. (PMID: 26706294)
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3299-303. (PMID: 11248073)
Curr Opin Allergy Clin Immunol. 2009 Dec;9(6):537-43. (PMID: 19680119)
Int Arch Allergy Immunol. 1996 Dec;111(4):396-402. (PMID: 8957114)
Eur Respir J. 2004 Nov;24(5):758-64. (PMID: 15516669)
فهرسة مساهمة: Keywords: Allergen immunotherapy; RQLQ(S); intralymphatic immunotherapy; quality of life; rhinoconjunctivits; symptom scores
تواريخ الأحداث: Date Created: 20231002 Latest Revision: 20231030
رمز التحديث: 20231031
مُعرف محوري في PubMed: PMC10509981
DOI: 10.1016/j.jacig.2022.09.007
PMID: 37780115
قاعدة البيانات: MEDLINE
الوصف
تدمد:2772-8293
DOI:10.1016/j.jacig.2022.09.007